Published in J Clin Oncol on September 11, 2006
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin (2011) 2.57
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol (2014) 2.18
Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther (2009) 2.10
Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology (2012) 1.71
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients. Int J Clin Oncol (2011) 1.62
Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol (2007) 1.55
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer (2010) 1.46
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecol Oncol (2007) 1.44
Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39
Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol (2009) 1.34
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol (2009) 1.18
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd (2013) 1.15
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene (2011) 1.12
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer (2012) 1.11
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer (2011) 1.09
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res (2010) 1.08
Treatment for recurrent ovarian cancer-at first relapse. J Oncol (2009) 1.08
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int (2012) 1.07
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov (2015) 1.06
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol (2014) 1.05
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma (2010) 1.02
Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol (2013) 1.02
Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract (2012) 1.01
Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res (2011) 0.97
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol (2013) 0.97
Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase. J Biol Chem (2008) 0.94
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer (2008) 0.93
The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. J Ovarian Res (2014) 0.92
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol (2015) 0.91
Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol (2010) 0.91
Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer Res (2010) 0.91
Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res (2010) 0.91
Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford) (2010) 0.91
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer (2011) 0.90
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol (2015) 0.90
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer (2011) 0.87
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer (2011) 0.87
Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecol Oncol (2010) 0.87
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig (2011) 0.87
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res (2012) 0.86
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.85
Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. Onco Targets Ther (2014) 0.85
Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag (2010) 0.85
Ovarian cancer treatment: The end of empiricism? Cancer (2015) 0.85
Major clinical research advances in gynecologic cancer in 2010. J Gynecol Oncol (2010) 0.85
Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol (2013) 0.84
SEOM guideline in ovarian cancer 2014. Clin Transl Oncol (2014) 0.84
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol (2009) 0.84
Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. Mol Clin Oncol (2013) 0.83
The role of hormonal factors and endocrine therapy in ovarian cancer. Contemp Oncol (Pozn) (2013) 0.83
Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer. Gynecol Oncol (2015) 0.82
Chemotherapy of ovarian cancer in elderly patients. Cancer Biol Med (2015) 0.82
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience. Langenbecks Arch Surg (2014) 0.82
Mucinous cystadenocarcinoma of the pancreas - outcome following different modes of treatment. Ann Gastroenterol (2011) 0.82
Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen? Gynecol Oncol (2012) 0.81
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer. Cancer (2014) 0.81
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. Int J Gynecol Cancer (2013) 0.81
The role of secondary surgery in recurrent ovarian cancer. Int J Surg Oncol (2012) 0.81
Major clinical research advances in gynecologic cancer 2009. J Gynecol Oncol (2009) 0.81
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol (2009) 0.80
Chemotherapy: A new standard combination for recurrent ovarian cancer? Nat Rev Clin Oncol (2010) 0.80
Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol (2013) 0.80
Introduction to managing patients with recurrent ovarian cancer. EJC Suppl (2015) 0.80
Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma. J Vet Intern Med (2011) 0.79
The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. J Cancer Res Clin Oncol (2010) 0.78
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther (2013) 0.78
Doublet chemotherapy in the elderly patient with ovarian cancer. Oncologist (2012) 0.78
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother (2013) 0.78
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol (2011) 0.77
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. Br J Cancer (2011) 0.77
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors. Invest New Drugs (2016) 0.77
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther (2013) 0.76
The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer. Int J Clin Oncol (2013) 0.76
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget (2016) 0.76
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol (2013) 0.76
Recent advances in systemic treatments for ovarian cancer. Cancer Imaging (2012) 0.76
Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. Mol Pharm (2014) 0.76
Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer. Curr Oncol Rep (2007) 0.75
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study. J Ovarian Res (2016) 0.75
Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX. Onco Targets Ther (2013) 0.75
New developments in treatment of ovarian carcinoma: focus on trabectedin. Cancer Manag Res (2010) 0.75
Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration. J Gynecol Oncol (2014) 0.75
Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer. Br J Clin Pharmacol (2016) 0.75
An Example of Ovarian Cancer as a 'Chronic Disease Process' - 11-Year Survival with Multiple Treatments for Recurrent and Progressive Disease. Case Rep Oncol (2008) 0.75
Management of relapsed ovarian cancer: a review. Springerplus (2016) 0.75
Epithelial ovarian cancer: A case report. Exp Ther Med (2014) 0.75
Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy. Front Oncol (2016) 0.75
Recent studies that influence the chemotherapeutic paradigm in the management of advanced ovarian cancer. F1000 Med Rep (2010) 0.75
The Clinical Relevance of Beta Blockers in Ovarian Carcinoma: A Systematic Review. Geburtshilfe Frauenheilkd (2016) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (2012) 8.74
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol (2014) 6.28
MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet (2007) 5.63
Endometrial cancer. Lancet (2005) 5.50
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol (2005) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med (2012) 4.24
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol (2008) 4.24
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst (2003) 3.77
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res (2009) 3.76
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol (2008) 3.75
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol (2013) 3.67
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol (2007) 3.53
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol (2010) 3.46
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst (2013) 3.46
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72
Clinical outcome after radical excision of moderate-severe endometriosis with or without bowel resection and reanastomosis: a prospective cohort study. Ann Surg (2014) 2.71
Absolute cardiovascular disease risk and shared decision making in primary care: a randomized controlled trial. Ann Fam Med (2008) 2.59
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol (2011) 2.56
Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol (2005) 2.54
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol (2010) 2.54
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 2.50
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol (2012) 2.48
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003) 2.44
The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up. Dtsch Arztebl Int (2015) 2.35
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst (2008) 2.35
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol (2012) 2.32
Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. J Clin Oncol (2007) 2.31
Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.26
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol (2013) 2.26
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst (2008) 2.20
Clinical management of uterine sarcomas. Lancet Oncol (2009) 2.18
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst (2003) 2.14
Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol (2009) 2.14
Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol (2011) 2.10
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can (2007) 2.09
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer (2011) 2.09
Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst (2008) 2.08
Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep (2012) 2.08
Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol (2008) 2.01
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol (2005) 1.99
Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer (2008) 1.94
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst (2005) 1.90
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst (2006) 1.86
Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet (2011) 1.84
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol (2010) 1.84
Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. Am J Obstet Gynecol (2007) 1.80
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma (2010) 1.79
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res (2009) 1.78